SCP
PRVB

Silverleafe Capital Partners’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Silverleafe Capital Partners’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-20,000
Closed -$298K – 82
2019
Q4 		$298K Hold
20,000
– – 0.17% 61
2019
Q3 		$137K Hold
20,000
– – 0.09% 62
2019
Q2 		$242K Hold
20,000
– – 0.15% 56
2019
Q1 		$46K Buy
+20,000
New +$46.9K 0.03% 72

Other funds holding PRVB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Silverleafe Capital Partners's PRVB Position: Q1 2020 in Review

Silverleafe Capital Partners sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2020, closing a stake of 20,000 shares — an estimated $298K sold.

Silverleafe Capital Partners first reported a position in PRVB in Q1 2019 and held it in 4 quarters. The position peaked at $298K in Q4 2019. 63 funds tracked by Wall St. Rank hold PRVB as of Q1 2020.

  • Silverleafe Capital Partners reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Silverleafe Capital Partners sold 20,000 Provention Bio, Inc. Common Stock shares in Q1 2020, an estimated $298K.
  • Silverleafe Capital Partners first reported a position in Provention Bio, Inc. Common Stock in Q1 2019 and held it in 4 quarters.
  • Silverleafe Capital Partners's Provention Bio, Inc. Common Stock position peaked at $298K in Q4 2019.
  • 63 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2020.

Based on Silverleafe Capital Partners's 13F filing for Q1 2020, filed 7 Apr 2020.